Survodutide
aka BI 456906
Mechanism
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Identification
| CAS number | 2805997-46-8 |
|---|---|
| Molecular formula | C192H289N47O61 |
| Typical dose | 0.3–2.7 mg once weekly subcutaneous (clinical trials; Phase II/III dose-escalation) |
| Half-life | ~6 days |
Vendors selling Survodutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Orbitrex Peptides | 10 mg | $99.99 | — | 95 |
| Skye Peptides | — | $89.00 | — | 90 |
| Peptidology | 10 mg | $79.99 | — | 89 |
| Qihang Peptide | — | — | — | 87 |
| EZ Peptides | 10 mg | $78.00 | — | 85 |
| Qing Li Peptide | — | — | — | 63 |
| Peptiatlas | — | — | — | 51 |
| HongDa Peptide | — | $343.00 | — | 43 |
| zztai Peptide Ltd | 10 mg | $257.00 | — | 43 |
| MJT peptides | 10 mg | $321.00 | — | 39 |
| Kimera Chems | — | $99.99 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 10 mg | $200.00 | — | — |
| Paramount Peptides | 6 mg | $225.00 | — | — |
| Peptira | — | $89.00 | — | — |
| Polaris Peptides | 5 mg | $75.00 | — | — |
| Solution Peptides | 12 mg | $100.00 | — | — |
| True Peptide | 10 mg | $120.00 | — | — |
| Wellness Peptides | — | $90.00 | — | — |
| realpeptides.co | — | $240.00 | — | — |
Research
Aims This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.
source →What is this review about? This review provides an overview of a medication called survodutide. Survodutide is not yet approved for use but is currently being tested to treat people living with obesity , as well as those living with MASH (metabolic dysfunction-associated steatohepatitis).
source →Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) dual agonist with the potential to induce greater weight reductions than GLP-1R mono-agonists.
source →Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases.
source →Background Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.
source →Background Metabolism-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide.
source →Survodutide is a novel GCG/GLP-1 receptor (GCGR/GLP-1R) dual agonist in clinical development for people with obesity and people with metabolic dysfunction-associated steatohepatitis (MASH).
source →Introduction Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects.
source →Survodutide represents an innovative approach to obesity management and metabolic-associated fatty liver disease (MAFLD). These conditions, often closely linked with type 2 diabetes (T2DM) and cardiovascular diseases, demand effective treatment strategies.
source →Glucagon-like-peptide-1 receptor (GLP-1R) agonists are under development as new drugs to treat type 2 diabetes, liver disease, obesity and cardiovascular diseases. Some of these drugs are solely agonists of the GLP-1R.
source →The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly. During study visits, the doctors collect information about participants' health.
source →This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
source →This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH…
source →This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2. Survodutide is a medicine being developed to help people with overweight or obesity.
source →This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications.
source →This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is taken up in the body.
source →This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight.
source →This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis.
source →